Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study
- PMID: 40417954
- PMCID: PMC12128625
- DOI: 10.2340/actadv.v105.42198
Efficacy and Safety of Dupilumab vs Narrowband UVB for the Treatment of Chronic Hand Dermatitis: A Retrospective Study
Conflict of interest statement
MKB, NS, and MB declared no conflict of interest. AC and MAB served as consultants and received honorarium from AbbVie, Biojamp, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Incyte, Janssen, Leo, Lilly, Medexus, Novartis, Pfizer, Recodrdati, Sanofi Regeneron, and Sun Pharma.
References
LinkOut - more resources
Full Text Sources
